Clinical trials: Metastatic Colorectal Cancer, completed
Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
The purpose of the phase 2 component of this study is to determine if giving the immune molecule NPC-1C to individuals who have cancer of the pancreas or gastrointestinal tract (colon or rectum) which has not responded to…
- Trial name
- NCT01040000
- Testing
- NPC-1C/NEO-102
- Where
- 6 sites in United States
- Volunteers
- 94 people
- Sponsor
- Precision Biologics, Inc
Hepatocellular Carcinoma
Trial of TG4023 Combined With Flucytosine in Liver Tumors
This trial is a phase I, open-label, dose-escalating study of the safety or percutaneous intra-tumoral injection of TG4023 (MVA-FCU1) combined with systemic administration of 5-fluorocytosine in patients with primary or secondary…
- Trial name
- NCT00978107
- Testing
- MVA-FCU1, flucytosine
- Where
- 6 sites in France
- Volunteers
- 16 people
- Sponsor
- Transgene
Solid Cancer
Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)
The primary objective of this study is to evaluate the safety of TSA-CTL in the treatment of advanced solid tumors. The secondary objective of this study is to evaluate preliminarily the effect of TSA-CTL in the treatment of…
- Trial name
- NCT02959905
- Testing
- TSA-CTL, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 11 people
- Sponsor
- BGI, China
Cancer
Care of Cancer Patients With Bowel Injury Caused by Radiation Therapy to the Pelvis
RATIONALE: A step-by-step procedure may help health care practitioners diagnose and treat cancer patients with bowel injury symptoms caused by radiation therapy.
- Trial name
- NCT00737230
- Testing
- educational intervention, questionnaire administration, assessment of therapy complications
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Colon Adenocarcinoma, Rectal Adenocarcinoma
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
This randomized phase II trial studies how well lower-dose compared to standard dose regorafenib works in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other places in…
- Conditions
- Colon Adenocarcinoma, Rectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7
- Trial name
- NCT02368886
- Testing
- Clobetasol Propionate, Pharmacological Study, Quality-of-Life Assessment
- Where
- 22 sites in United States
- Volunteers
- 123 people
- Sponsor
- Academic and Community Cancer Research United
Recurrent Colon Cancer, Recurrent Rectal Cancer
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
This phase I trial is studying the side effects and best dose of suberoylanilide hydroxamic acid when given together with fluorouracil, leucovorin, and oxaliplatin in treating patients with progressive metastatic or unresectable…
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer
- Trial name
- NCT00138177
- Testing
- oxaliplatin, leucovorin calcium, vorinostat
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
This study is being done to determine the maximum dose of a certain chemotherapy drug (irinotecan) that can be tolerated as part of a combination of drugs.
- Trial name
- NCT01183494
- Testing
- FOLFIRI, Avastin, Irinotecan
- Where
- 2 sites in United States, Italy
- Volunteers
- 17 people
- Sponsor
- University of Chicago
Colorectal Neoplasms
Stivarga Regulatory Post-Marketing Surveillance Study in Korea
To investigate and collect post-marketing data on the safety of Stivarga in real world practice in its registered indication(s) as required by Health Authority.
- Trial name
- StivargaPMS (NCT02106858)
- Testing
- Regorafenib (Stivarga,BAY73-4506)
- Where
- South Korea
- Volunteers
- 316 people
- Sponsor
- Bayer
Colorectal Cancer
Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer receiving chemotherapy may help doctors understand the effect of chemotherapy on biomarkers.
- Trial name
- NCT00559676
- Testing
- capecitabine, fluorouracil, irinotecan hydrochloride
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospital Regional Universitaire de Limoges
Wild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer
Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer
The aim of this study was to evaluate the efficacy and safety of continuing cetuximab combined with chemotherapy after first-line progression in wild-type KRAS,NRAS and BRAF colorectal cancer.
- Trial name
- NCT04718038
- Testing
- Cetuximab combind mFOLFOX6/FOLFIRI
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Henan Cancer Hospital
Colorectal Cancer, Metastatic Cancer
Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as leucovorin, fluorouracil, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544349
- Testing
- cetuximab, fluorouracil, leucovorin calcium
- Where
- 7 sites in France
- Volunteers
- 45 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Metastatic Colorectal Cancer, Liver Metastases
FOLFIRI and Sunitinib in Metastatic Colorectal Cancer
This is an open label single arm prospective multicenter Phase II study in around 20 patients. The primary objective of this study is to evaluate whether the addition of sunitinib to FOLFIRI results in a significant reduction of…
- Trial name
- NCT00806663
- Testing
- sunitinib added to FOLFIRI
- Where
- 4 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Central European Society for Anticancer Drug Research
Neoplasms, Colorectal
Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer
Subjects will be entered into cohorts of 3 for the dose escalation phase so that the maximum tolerated dose can be determined. 18 additional patients will be recruited once the maximum tolerated dose (MTD) is determined for…
- Trial name
- NCT00540943
- Testing
- Pazopanib, Cetuximab, Irinotecan
- Where
- 2 sites in France
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Metastatic Colorectal Cancer
Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.
Iron deficiency has a high prevalence in colorectal cancer patients ranging at ca. 60%. About 70% of these patients suffer from iron deficiency anemia (IDA) which adds both physical and cognitive impediments to an already…
- Trial name
- NCT02469480
- Testing
- FerInject, Ferro sanol
- Where
- 18 sites in Germany
- Volunteers
- 64 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer
RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients
Interventional, prospective, randomized (1:1), controlled, open label, multicenter phase IIb study in patients with advanced metastatic colorectal cancer.
- Trial name
- RAMTAS (NCT03520946)
- Testing
- Ramucirumab, TAS 102
- Where
- 28 sites in Germany
- Volunteers
- 430 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer, Metastatic Cancer
Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
RATIONALE: Radiofrequency ablation may be able to shrink or destroy cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00004142
- Testing
- Floxuridine, Fluorouracil (5-FU), Conventional surgery
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00039273
- Testing
- panitumumab
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Colorectal Neoplasms
Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety and efficacy of Abraxane (nab-paclitaxel) in subjects with previously treated metastatic colorectal cancer.
- Trial name
- NCT02103062
- Testing
- ABI-007
- Where
- 6 sites in France
- Volunteers
- 41 people
- Sponsor
- Celgene
Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma
Oral Rigosertib for Squamous Cell Carcinoma
The primary objective of this study is to determine if tumors in patients with papillomavirus (HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard therapy will decrease in size following…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT01807546
- Testing
- rigosertib
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Traws Pharma, Inc.
Circulating Markers, Metastatic Colorectal Cancer
Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer
The chemotherapy monitoring is currently based on radiological (RECIST 1.1 guideline) and clinical evaluation every 3 months. Circulating markers as Carcino Embryonic Antigen (CEA), circulating tumour DNA and total cell free DNA…
- Trial name
- COCA-MACS (NCT02872779)
- Testing
- Blood sampling for free mutant DNA analysis
- Where
- France
- Volunteers
- 74 people
- Sponsor
- University Hospital, Rouen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.